Related Experiment Video
Updated: Dec 9, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.3K
Biological treatments for severe asthma
1Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Yeungnam University Journal of Medicine
|September 11, 2020
Summary
Severe asthma, a condition affecting a small percentage of patients, incurs high healthcare costs. Biologic therapies, particularly those targeting type 2 inflammation, offer new treatment options, improving patient outcomes and quality of life.
Area of Science:
- Pulmonology and immunology
- Pharmacology
Background:
- Severe asthma affects 3-13% of asthma patients, leading to disproportionately high healthcare utilization and costs.
- Limited effective treatment options exist for severe asthma, highlighting the need for novel therapeutic approaches.
Purpose of the Study:
- To review the mechanisms of action and indications for currently approved biologic therapies for severe asthma.
- To discuss key considerations for selecting appropriate biologic treatments for individual patients.
Main Methods:
- Literature review of approved biologic therapies for severe asthma.
- Analysis of clinical trial data and real-world evidence on biologic efficacy and safety.
Main Results:
- Biologic therapies, primarily targeting type 2 inflammation, have demonstrated significant benefits in severe asthma management.
- These benefits include reduced asthma symptoms, improved lung function, decreased oral corticosteroid use, and enhanced quality of life.
Conclusions:
- Biologics represent a promising advancement in the treatment of severe asthma, particularly for patients with type 2 inflammation.
- Careful patient selection based on inflammatory profiles and treatment goals is crucial for optimizing biologic therapy outcomes.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
2.9K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.9K
01:20Asthma: Pathogenesis and Management
1.0K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.0K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
01:26Asthma-II: Pathophysiology and Classification
3.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.8K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.5K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.5K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K